Plexxikon Inc and Roche, announced that they have entered into an agreement to develop and commercialize a second novel kinase inhibitor, PLX5568. The main focus of this partnership will be the development of this small molecule inhibitor of Raf kinase as an oral therapeutic treatment for polycystic kidney disease (PKD). There is currently no registered treatment for PKD which affects over 600,000 patients in the US and is the most common life-threatening genetic disease.
This agreement with Plexxikon in PKD is consistent with the overall mission of Roche to address diseases with significant unmet medical need. Plexxikon is evaluating PLX5568 in an ongoing phase-1 human clinical trial.
"PLX5568 is yet another first-in-class compound from Plexxikon that further highlights our platform's capability to develop highly selective kinase inhibitors. We hope PLX5568 will significantly delay the loss of kidney function due to this debilitating disease, leading to improved quality of life for patients," stated K Peter Hirth, chief executive officer of Plexxikon. "We are pleased to announce our second collaboration with Roche, building on the foundation of an excellent and continuing partnership centered on our oncology programme and lead product candidate, PLX4032."
"We are enthusiastic about collaborating with Plexxikon on this program. We have built a strong relationship through our partnership on PLX4032. Together, we will advance PLX5568 to help patients suffering from PKD." said Dan Zabrowski, Global Head of Pharma Partnering at Roche. "Plexxikon has demonstrated excellent capabilities in discovery and early development necessary to bring forward novel and differentiated product candidates in a variety of indications. These capabilities have driven our interest in a second collaboration with Plexxikon."
A proprietary Scaffold-Based Drug Discovery platform has enabled Plexxikon's position as a leader in structure-guided discovery and development of novel first-in-class small molecule pharmaceuticals to treat human disease.